Admedus herpes 2015,herpes simplex virus fetal consequences,ways to save your body energy levels - Good Point

admin 24.01.2014

Australian-based Admedus (ASX:AHZ), which is building a diversified healthcare company, is set for a key value inflection point in its immunotherapy platform this year, with anticipated interim results from a Phase 2 trial of its therapeutic vaccine for the treatment of herpes simplex virus-2 (HSV-2). The company is also expanding the commercial reach of its CardioCel heart patch, which is now being used in more than 95 heart centers around the world to treat congenital heart defects.
The company is targeting therapeutic vaccines for infectious disease (HSV-2) and in oncology for the treatment of human papillomavirus (HPV). The company’s first commercial product from ADAPT is CardioCel, a bio-scaffold for cardiovascular repairs, which Admedus commercialized in 2015. Off-the-shelf CardioCel is now being used as a prosthetic tissue for corrective surgery in patients with congenital heart disease (CHD) in the U.S.
CardioCel is also on the market in Hong Kong and Singapore and Admedus has partnered with Genpharm to distribute CardioCel in the Middle East and North Africa.
While a TAVR stent addresses blood backflow in the heart, it doesn’t reconstruct a natural valve. In terms of outcomes, studies show that the survival rate of patients is higher in those that have had their valves reconstructed, compared with a repair.

Traditionally, aortic valves have been replaced with a bio-prosthetic or mechanical heart valve, instead of being surgically repaired, as surgeons haven’t had a tissue that can withstand such a high pressured area within the heart until now, Dr.
CardioCel has been proven to have the high tensile strength to work in a pressured environment, as well as having the added benefit of not calcifying like other tissues, and instead actively facilitates host tissue regeneration, he adds. Admedus is also using ADAPT to generate additional regenerative tissue products, targeting vascular tissue repairs, dura mater repair of the membrane surrounding the brain and spinal cord, stem cell or stem cell factor delivery, abdominal and hernia repair, and gynecological repair. The company is planning to file for regulatory approval of potential additional products between 2017 and 2020.
Chick explains that Admedus’ patented DNA platform technology for the delivery of novel immunotherapies uses a combination of intra-dermal delivery, proprietary codon optimization and the protein, ubiquitin, added in the codon to help stimulate a T-cell response. Chick says the company’s HPV vaccine is designed to target and clear HPV-positive tumor cells. Chick points out that patients in a pivotal trial are now entering their seventh year of follow-up, without any reported adverse events after correction of simple and more complex congenital cardiac defects. CardioCel, on the other hand, is sewn in to reconstruct the leaflets and is eventually populated with stem cells to become part of the heart, enabling full movement of the valve.

Admedus will be presenting on this topic at the annual meeting of the European Association for Cardio-Thoracic Surgery in October. The company is hoping to demonstrate that its vaccine can improve viral load, shedding and flare frequency, as well as show continued safety. It has generated strong preclinical data by preventing disease progression and inhibiting tumor formation.
Admedus is using direct sales teams in North America, Europe and Asia, initially targeting CHD clinics and moving into adult cardiovascular centers.

At home remedies for herpes on lip
Genital herpes 6 weeks early
Medical researcher career salary
Alternative breast cancer treatment centers 5x5
  • PRINS_666, 24.01.2014 at 18:26:24
    Preliminary symptoms for the primary outbreak of genital.
  • PARTIZAN, 24.01.2014 at 13:53:50
    Causes a bigger share of latest and decided to do more analysis reductions At Six Months Although.
  • kvazemorda, 24.01.2014 at 20:37:42
    Have been protected against a lethal dose.